Dengue Vaccine Market 2025 Revenue and Future Expansion

Dengue Vaccine Market Size, Key Players with Growth and Opportunities

The global dengue vaccine market size is calculated at US$ 751.01 million in 2025, grew to US$ 839.14 million in 2026, and is projected to reach around US$ 2297.33 million by 2035. The market is expanding at a CAGR of 11.74% between 2026 and 2035.

The government's efforts to encourage vaccination programs, growing awareness of the severity of dengue and the shortcomings of current treatment options, and continuous research and development that is enhancing vaccine efficacy and safety profiles are all contributing factors to the dengue vaccine market's expansion. At the forefront are major firms such as Sanofi and Takeda, which leverage strategic alliances and comprehensive clinical studies to drive innovation and market penetration.

Key Takeaways

• Dengue vaccine industry poised to reach USD 751.01 million by 2025.
• Forecasted to grow to USD 2297.33 million by 2035.
• Expected to maintain a CAGR of 11.74% from 2026 to 2035.
• North America dominated the dengue vaccine market in 2024.
• Asia Pacific is expected to grow at the fastest CAGR during the forecast period.
• By type, the live attenuated vaccine segment dominated the market in 2024.
• By type, the nucleic acid-based vaccine segment is expected to grow at the fastest CAGR during the forecast period.
• By treatment, the anti-allergic segment dominated the market in 2024.
• By treatment, the blood thinners segment is expected to grow at the fastest CAGR during the forecast period.
• By route of administration, the parenteral segment dominated the market in 2024.
• By route of administration, the oral segment is expected to grow at the fastest CAGR during the forecast period.
• By end-users, the hospitals segment dominated the market in 2024.
• By end-users, the specialty clinics segment is expected to grow at the fastest CAGR during the forecast period.
• By distribution channel, the hospital pharmacy segment dominated the dengue vaccine market in 2024.
• By distribution channel, the online pharmacy segment is expected to grow at the fastest CAGR during the forecast period.

Quick Facts Table

What is the Dengue Vaccine?

The sector devoted to the creation, manufacturing, and marketing of vaccinations intended to prevent dengue disease is known as the dengue vaccine market. Another significant driver of market expansion is the growing funding and assistance provided by governmental and non-governmental organizations for the development and dissemination of dengue vaccines. Increased healthcare resources and public-private partnerships are being used to hasten the release of vaccines in dengue-endemic regions.

In the WHO Region of Europe (EURO), the Regions of the Americas (PAHO), South-East Asia and West Pacific Regions (SEA RO and WPRO, respectively), the Eastern Mediterranean WHO Region (EMRO), and Africa, 101 countries and territories have reported more than 4 million dengue cases and more than 2500 dengue-related deaths since the start of 2025.

Dengue Vaccine Market Outlook

• Industry Growth Overview: Over the years 2025–2034, the market is anticipated to grow significantly and undergo dynamic evolution. Strong public health campaigns, technological developments in vaccine development, and an increasing worldwide disease burden will all contribute to this expansion.
• Global Expansion: The growing global dengue burden and the release of new, more potent vaccines like Qdenga are expected to propel the dengue vaccine market's significant growth. Due in large part to rising awareness and demand for travel, this expansion will be most noticeable in the main endemic regions of Asia-Pacific and Latin America, but it will also grow in North America and Europe.
• Major Investors: Pharmaceutical behemoths Takeda, Sanofi, GlaxoSmithKline (GSK), and Merck are among the major investors in the development of dengue vaccines, as are important players like the Serum Institute of India and Panacea Biotec. These organizations frequently work with research organizations like the Indian Council of Medical Research (ICMR) and the U.S. National Institutes of Health (NIH).

What is the Role of AI in the Dengue Vaccine Market?

AI plays a crucial role in market growth, as it has become a significant part of vaccine development. From initial research to formulation to clinical trials, and other aspects of vaccine development. AI's incorporation into vaccine development is a revolutionary step that will speed up the process, improve accuracy, and increase our knowledge of infectious diseases.

Segmental Insights

Type Insights

Which Vaccine Type Dominated the Dengue Vaccine Market in 2024?

The live attenuated vaccine segment dominated the market in 2024 because one of the most effective and economical medical interventions in history has been the use of live attenuated vaccines to prevent human viral diseases. Live attenuated vaccines can be produced at a relatively low cost, can be given orally, stimulate a variety of immune responses, produce quick, lasting immunity, frequently eliminate the need for booster shots, and don't require adjuvants.

Nucleic Acid-Based Vaccine

The nucleic acid-based vaccine segment is expected to grow at the fastest CAGR in the dengue vaccine market during the forecast period because platforms based on nucleic acids, such as DNA and mRNA vaccines, have become viable substitutes because of their capacity to stimulate robust immune responses, speed up development, and enable scalable production.

Chimeric Live Attenuated Vaccine

The chimeric live attenuated vaccine segment is expected to grow significantly in the market during the forecast period. Researchers have created affordable chimeric vaccines that can quickly reach a large population in response to outbreaks of terrible diseases. In a single formulation, these vaccines can offer complete protection against a variety of pathogens. The design of chimeric vaccines can benefit greatly from omics-based research. Researchers are now able to create stable and highly immunogenic chimeric antigens thanks to recent developments in bioinformatics tools.

Route of Administration Insights

How Parenteral Segment Dominated the Dengue Vaccine Market in 2024?

The parenteral segment dominated the market in 2024 because vaccines administered parenterally have proven to be a very successful method of preventing and managing infectious diseases. These pathways have a number of benefits, such as improved vaccine stability, strong immune response induction, and quick and effective antigen delivery to the immune system.

Oral

The oral segment is expected to grow at the fastest CAGR during the forecast period because they are less invasive, easier to administer, safer overall, and less expensive than injectable vaccines. Oral vaccines are becoming more and more popular. Furthermore, because oral vaccinations avoid the blood vessels and circulatory system, they are a preferable option for people with compromised immune systems.

End-Users Insights

Why did Hospitals Dominate the Dengue Vaccine Market in 2024?

The hospitals segment dominated the market in 2024. During mass vaccination campaigns, hospitals are essential for delivering vaccines to the general public. They possess the facilities, medical staff, and knowledge required to effectively and efficiently reach a sizable population. Because of their accessibility and capacity to offer a wide range of medical services, hospitals are frequently chosen as vaccination locations.

Specialty Clinics

The specialty clinics segment is expected to grow at the fastest CAGR in the dengue vaccine market during the forecast period. Vaccination services are provided by specialty clinics, and people frequently choose them for a variety of reasons, such as convenience, individualized treatment, access to specialized knowledge, and a greater selection of vaccines, including premium and optional ones.

Homecare

The homecare segment is growing significantly in the market during the forecast period because not only is at-home vaccination convenient, but it's also a wise, secure, and humane decision for a modern society that demands the best without sacrificing comfort or security. The advantages of home vaccination are genuinely revolutionary, ranging from lowering the risk of infection to facilitating prompt immunization and providing individualized care.

Distribution Channel Insights

Why Hospital Pharmacy Dominated the Dengue Vaccine Market in 2024?

The hospital pharmacy segment dominated the market in 2024. Pharmacists can assist with vaccination in a number of ways in a range of healthcare settings, according to their expertise and experience in providing vaccines. Hospital pharmacists will play a bigger part in vaccinations as hospitals grow, transform into health systems, and take on more responsibility for patient care.

Online Pharmacy

The online pharmacy segment is expected to grow at the fastest CAGR in the dengue vaccine market during the forecast period. The option to purchase vaccines directly from an internet pharmacy is probably going to grow in the future, but it will still be a highly regulated procedure that needs a legitimate prescription and expert administration. Instead of just sending the vaccine product to the customer's home, the main model will change to include integrated at-home vaccination services provided by authorized e-pharmacies.

Retail Pharmacy

The retail pharmacy segment is growing significantly in the market during the forecast period because, over the past ten years, retail pharmacies have become increasingly important in supplying the public with vaccines. Retail pharmacies are in a good position to provide a variety of preventive care services that can enable people to take control of their health because of their accessibility and the knowledge of pharmacists.

Regional Insights

Dengue Defense Drives Demand: North America's Proactive Push for Prevention and Vaccines

North America dominated the dengue vaccine market in 2024. The need for preventative vaccines is being driven by public health campaigns and growing dengue awareness in North America. Rapid vaccine uptake is made possible by the region's strong healthcare system and increased R&D funding. Additionally, the risks associated with international travel are increasing demand for travel safety measures, which is propelling the market's expansion.

Government Support Drives the Dengue Vaccine Market in the U.S.

Over the past five years, dengue cases have significantly increased worldwide, with the Americas seeing the most notable increases. In 2023, there were 4.6 million cases and 2,400 deaths in the Americas; in 2024, there were 13 million cases and 8,200 deaths. More than 760,000 dengue cases have been reported in 2025 as of March 6, a 15% increase over the previous 5-year average.

The CDC released a Health Update in March 2025 with the title "Ongoing Risk of Dengue Virus Infections and Updated Testing Recommendations in the United States." "Increased Risk of Dengue Virus Infections in the United States" was the title of a Health Advisory published by the CDC through the Health Alert Network in June 2024.

Climate Dengue Outbreaks: Increasing Demand for Vaccine in the Asia Pacific

Asia Pacific is estimated to host the fastest-growing dengue vaccine market during the forecast period because of their tropical wet and dry climates and increased susceptibility to dengue outbreaks. Nations like Thailand, Indonesia, India, and the Philippines are the only ones in Asia-Pacific where both demand and supply for dengue vaccines are increasing. Since this area accounts for nearly half of all dengue cases globally, vaccination is a crucial component of overall management.

What are the Dengue Vaccine Market Trends in India?

To ensure successful sanitation and vector control campaigns, the Union Health Minister emphasized the significance of strengthening inter-sectoral coordination among state health departments, public health engineering, irrigation departments, NGOs, municipal bodies, railroads, local government institutions, and disaster management authorities.

In 2024, the nation reported 2,33,519 cases of dengue and 297 fatalities. 42 fatalities and 49,573 cases have been reported as of August 31, 2025. Up until August 31st of this year, 964 cases were reported in Delhi, compared to 1,215 during the same period last year. There have been 1,646 cases reported from Uttar Pradesh, 298 from Haryana, and 1,181 from Rajasthan in the nearby NCR states.

In August 2024, the first-ever Phase 3 clinical trial for a dengue vaccine in India began, according to a statement from Panacea Biotec and the Indian Council of Medical Research (ICMR). The effectiveness of DengiAll, an indigenous tetravalent dengue vaccine created by Panacea Biotec in India, will be assessed in this historic trial.

Awareness Campaigns: A Major Driver in Europe

Europe is expected to grow at a significant CAGR in the dengue vaccine market during the forecast period because vaccination against dengue has been incorporated into public health plans in countries such as France and Spain, particularly for vulnerable groups. The significance of immunizations prior to travel has been highlighted by traveler awareness campaigns. The region's proactive approach is highlighted by the European Union's pledge to support studies on dengue prevention and mosquito control. These programs seek to safeguard public health and stop the spread.

Dengue Cases Skyrocketing in France

In France, the number of "indigenous" dengue fever cases is rapidly increasing. It is crucial to evaluate preventative measures for both tourists and the local French population, as dengue has the potential to become endemic in France. Over 4,000 imported cases of dengue, 18 chikungunya, and 5 Zika virus cases were reported as of October 30, 2024.

South America: Dengue Overload Fuelling Vaccine Demand

South America is expected to grow significantly in the dengue vaccine market during the forecast period. The Pan American Health Organization reported 6,253,754 dengue cases in the Americas through week 36, 2024, with 6,650 deaths. This surge has spurred major governments to purchase the QDENGA vaccine (two-dose tetravalent), increasing uptake and driving the market. The sheer volume of cases means healthcare systems demand preventive solutions, prompting broader access to vaccination beyond treatment alone.

Argentina’s Emergency Implies Rapid Market Uptick

In Argentina, cases exceeded 576,000 by Oct 2024 and had risen by over 2,153% year-on-year earlier in the season. This health crisis triggered a strategic plan for dengue control (2024-2025), including targeted vaccine programs in 48 identified zones. With such urgency, demand for vaccines has accelerated, pushing procurement and deployment growth ahead of traditional vectors.

MEA Region: Emerging Markets, Rising Need

The Middle East and Africa are expected to grow at a lucrative CAGR in the dengue vaccine market during the forecast period. Rising temperatures and 32,925 dengue cases across 13 nations in 2024 spurred collaborations among health ministries, vaccine trial authorizations, and donor-backed immunization funding, accelerating the emergence of the dengue vaccine market regionwide.

UAE: Strategic Prevention Boosts Vaccine Readiness

Following 306 dengue cases in 2024, the UAE intensified vector-control efforts, eliminated 409 breeding sites, and launched vaccine-readiness programs aligned with national health sustainability goals and climate resilience strategies.

Dengue Vaccine Market Value Chain Analysis

R&D

To establish basic safety and immunogenicity, preclinical studies in animal models and basic research on the dengue virus are the first steps in research and development (R&D). Finding viable vaccine candidates and selecting the most promising ones for additional testing are the tasks of this stage.

Top Companies Include: Sanofi, Teva, Takeda, GSK, Merck & Co., Johnson & Johnson, Roche, Novartis, Pfizer, AstraZeneca, and Eli Lilly. Merck & Co, etc.

Clinical Trials and Regulatory Approvals

Phase 1 of clinical trials evaluates safety in small groups; Phase 2 studies immune response and dosage in larger groups; and Phase 3 assesses safety and efficacy in endemic areas in thousands of people. After that, data is sent to national organizations or regulatory agencies like the FDA in the form of a Biological License Application (BLA) for approval.

Top Companies Include: Sanofi, Teva, Takeda, GSK, Merck & Co., Johnson & Johnson, Roche, Novartis, Pfizer, AstraZeneca, and Eli Lilly. Merck & Co, etc.

Patient Support and Services

A carefully thought-out vaccine rollout and long-term surveillance (Phase 4 trials) to track safety and effectiveness in the general population are part of patient support after approval. To guarantee proper administration, it consists of community education, precise dosage schedules (such as a three-dose series), and integration with current healthcare systems.

Top Companies Include: Merck & Co., Johnson & Johnson, Roche, Novartis, Pfizer, AstraZeneca, and Eli Lilly. Merck & Co, etc.

Company Landscape

Sanofi

Company Overview

Corporate Information

• Headquarters, Paris, France 
• Year Founded, 1973 (through the merger of several French pharmaceutical companies) 
• Ownership Type, Public, Listed on Euronext Paris and NASDAQ (as Sanofi S.A.) 

History and Background

• Sanofi's heritage traces back to the 18th and 19th centuries through various precursor companies like Laboratoires Midy and Hoechst.
• The modern company was established in 1973 by Elf Aquitaine.
• Its growth has been marked by a series of major mergers.

Key Milestones/Timeline

• In 1973, Sanofi was established in France.
• 1999, Merger with Synthélabo to form Sanofi-Synthélabo.
• 2004, Merger with Aventis to form Sanofi-Aventis.
• In 2011, the Company officially rebranded to Sanofi.
• 2015, Introduction of the first dengue vaccine, Dengvaxia (CYD-TDV), approved in the Philippines, though subsequent recommendations limited its use.
• 2024, Sanofi continues to focus on its 'Play to Win' strategy, emphasizing growth in key therapeutic areas.

Business Overview

A global healthcare company focused on human health through the discovery, development, manufacture, and marketing of pharmaceutical products and vaccines.

Business Segments/Divisions

Pharmaceuticals, Vaccines (Sanofi Pasteur), Consumer Healthcare.

Geographic Presence

Operates in over 70 countries worldwide, with a significant footprint in Europe, North America, and emerging markets.

Key Offerings

• Vaccines, Influenza (Vaxigrip), Meningitis (Menactra), Polio, Rabies, Tetanus, Diphtheria, Pertussis.
• Pharmaceuticals, Immunology (Dupixent), Oncology, Rare Diseases, Diabetes, Cardiovascular.
• Dengue Vaccine, Dengvaxia (CYD-TDV), a tetravalent live attenuated vaccine.

End-Use Industries Served

Hospitals and Specialty Clinics, Government and Public Health Agencies, Pharmacies, Retail Consumers.

Key Developments and Strategic Initiatives

• Mergers & Acquisitions

Focus on strategic acquisitions to strengthen its pipeline in areas like rare diseases, immunology, and digital health.

• Partnerships & Collaborations

Partnerships with academic institutions and biotechnology firms to accelerate R&D, including significant investments in mRNA technology collaborations.

• Product Launches/Innovations
  • Continual pipeline advancements in immunology and oncology. 
  • In April 2024, Sanofi launched Verorab (inactivated rabies vaccine) in the U.K. 

Capacity Expansions/Investments

Committed to substantial annual R&D vaccine investment, approximately €1 billion.

Regulatory Approvals

Dengvaxia is approved in several endemic countries, but its use is generally restricted by the WHO to individuals with confirmed prior dengue infection due to safety concerns in seronegative individuals.

Distribution channel strategy

Utilizes a global distribution network, targeting government-led immunization programs and private healthcare channels.

Technological Capabilities/R&D Focus

Focus on next-generation vaccines, including mRNA technology platforms, to address RSV, influenza, and other infectious diseases.

Core Technologies/Patents

Holdings related to its tetravalent live attenuated dengue vaccine platform (Dengvaxia)

Research & Development Infrastructure

Global R&D centers, with a focus on advanced R&D in areas like immunology, including a commitment to make Montpellier the global hub for translational research on autoimmune diseases (October 2025).

Innovation Focus Areas

Immunology and inflammation, rare diseases, oncology, and next-generation vaccines.

Competitive Positioning

• Strengths & Differentiators

Long-standing global leader in vaccines (Sanofi Pasteur), first-to-market advantage with Dengvaxia, and broad vaccine portfolio.

• Market presence & ecosystem role

Strong presence in key global vaccine markets, a critical supplier to global public health organizations.

SWOT Analysis

• Strengths: Established brand and global reach, leading vaccine portfolio, first-mover advantage in dengue.
• Weaknesses, Restrictions on Dengvaxia use due to safety profile in seronegative patients, reliance on older vaccine technology.
• Opportunities, Expansion of its broader vaccine portfolio (e.g., mRNA), and growth in emerging markets.
• Threats, Competition from newer dengue vaccines (Qdenga), stricter regulatory environment.

Recent News and Updates

Press Releases

• October 2025, Sanofi's high-dose influenza vaccine demonstrated superior protection for older adults against hospitalization versus standard-dose.
• October 2025, Q3 results showed continued sales and earnings progress.

Industry Recognitions/Awards

Continually recognized for its contributions to global health and vaccine innovation.

Takeda Pharmaceutical Company Limited

Company Overview

Corporate Information

• Headquarters, Tokyo, Japan
• Year Founded, 1781 (Business start), 1925 (Formal incorporation)
• Ownership Type, Public, Listed on Tokyo Stock Exchange and New York Stock Exchange (as Takeda).

History and Background

• Founded by Chobei Takeda I in 1781, selling traditional Japanese and Chinese herbal medicines in Osaka.
• Evolved into a modern pharmaceutical manufacturer by the late 19th century, importing Western medicines and establishing manufacturing facilities.

Key Milestones/Timeline

• 1781, Chobei Takeda I starts the medicine business.
• 1925, Formal establishment of Takeda Pharmaceutical Company Limited.
• 2019, Completed acquisition of Shire plc, transforming Takeda into a global biopharmaceutical leader.
• 2022, Takeda's dengue vaccine, Qdenga (TAK-003), received its first major regulatory approval (Indonesia).
• May 2024, WHO Prequalification of Qdenga, opening the door for procurement by UN agencies.

Business Overview

A patient-focused, values-based, R&D-driven global biopharmaceutical company focusing on five key business areas.

Business Segments/Divisions

• Gastroenterology, Rare Diseases, Plasma-Derived Therapies (PDT), Immunology, Oncology, Neuroscience, and Vaccines.
• Vaccines are a key growth area, with revenue from the segment accounting for approximately 8% of total revenue in FY2024.

Geographic Presence

Operates in over 80 countries and regions, with significant operations in Japan, the U.S., and Europe.

Key Offerings

• Dengue Vaccine, Qdenga (TAK-003), a live-attenuated tetravalent vaccine based on a dengue serotype two backbone.
• Other Vaccines, Influenza, Polio, Rotavirus, Measles, Mumps, Rubella.
• Pharmaceuticals, Entyvio (Gastroenterology), Takhzyro (Rare HAE), Immunoglobulin therapies.

End-Use Industries Served

Hospitals and Specialty Clinics, Government and Public Health Agencies (via immunization programs), Pharmacies.

Key Developments and Strategic Initiatives

• Mergers & Acquisitions

Major acquisition of Shire plc in 2019 for approximately $62 billion, which diversified its product portfolio and global footprint.

• Partnerships & Collaborations
  • Collaboration with the U.S. Centers for Disease Control and Prevention (CDC) on vaccine research.
  • Partnership with Biological E. Limited (India) for local production and scale-up of Qdenga, including multi-dose vials, with a target of 100 million doses annually by the end of the decade (February 2024).

Product Launches/Innovations

Launched Qdenga (TAK-003) as a second-generation dengue vaccine.

Capacity Expansions/Investments

Focusing on scaling up global manufacturing capacity for Qdenga, with the German facility as a primary hub and Biological E. as a key partner for future volumes and public health formats.

Regulatory Approvals

• Qdenga has been approved in over 40 countries, including the EU, UK, Indonesia, Thailand, Argentina, and Brazil, and received WHO Prequalification in May 2024.
• Added to the expanded immunization schedules in Brazil and Indonesia in May 2024.

Distribution channel strategy

Strategic focus on public health programs, leveraging the WHO Prequalification for procurement by organizations like UNICEF and PAHO, alongside private market distribution.

Technological Capabilities/R&D Focus

Core technology based on a live-attenuated tetravalent vaccine, utilizing a serotype two backbone to induce robust immunity against all four serotypes (DENV-1 to DENV-4).

Core Technologies/Patents

Proprietary technology related to the DENV-2 backbone vaccine approach, Takeda's tetravalent dengue vaccine platform.

Research & Development Infrastructure

Global R&D network, including the pivotal TIDES study involving 20,000 participants across dengue-endemic countries.

Innovation Focus Areas

Complex infectious diseases, rare diseases, and advanced cell and gene therapies.

Competitive Positioning

Strengths & Differentiators

Qdenga's favorable profile for both seropositive and seronegative individuals (approved for use regardless of prior dengue exposure), strong efficacy against hospitalization, and WHO Prequalification (May 2024).

Market presence & ecosystem role

Rapidly growing presence in dengue-endemic countries, emerging as the preferred option for public health programs due to its broader label.

SWOT Analysis

• Strengths: Superior product profile for Qdenga over the current market leader, strong clinical efficacy data, robust global manufacturing network (including Biological E. partnership).
• Weaknesses: Second-to-market position, requires a two-dose schedule.
• Opportunities, replacing Dengvaxia in government programs, rapid growth in Asia-Pacific and Latin America.
• Threats, Potential new entrants to the market, and global logistical challenges of large-scale rollouts.

Recent News and Updates

Press Releases,

• Qdenga (TAK-003) Q4 FY2024 (April 2024-March 2025) Revenue was JPY 35.6 billion (+259% growth).
• April 29, 2025, announced plan to launch Qdenga in India by 2026 via partnership with Biological E.

Industry Recognitions/Awards

Qdenga's WHO Prequalification in May 2024 is a significant endorsement and key driver of global adoption.

Top Vendors in the Dengue Vaccine Market & Their Offerings

Top Companies in the Dengue Vaccine Market 

• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• GSK plc (U.K.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• BIO-MED (India)
• Intercept Pharmaceuticals, Inc. (U.K.)
• Emcure Pharmaceuticals Ltd (India)
• Changchun BCHT Biotechnology Co. (China)
• Novo Medi Sciences Pvt. Ltd. (India)
• Biological E. Limited (India)
• Panacea Biotec Ltd. (India)
• Merck & Co., Inc.
• Johnson & Johnson
• GeneOne Life Science
• Medigen Vaccine Biologics
• Sun Pharmaceutical Industries Ltd.
• Serum Institute of India Pvt. Ltd.
• Biological E, and VabioTech

Recent Developments in the Dengue Vaccine Market

• In June 2025, Merck, which is referred to as MSD outside of the US and Canada, announced the start of the MOBILIZE-1 Phase 3 clinical trial, which will assess the safety, immunogenicity, and effectiveness of a single dose of the investigational quadrivalent vaccine V181 in preventing dengue.
• In May 2025, in partnership with Biological E, the Japanese pharmaceutical company Takeda intends to introduce its dengue vaccine, Qdenga, in India the following year. The company hopes to obtain a license by 2026 and is currently conducting clinical trials.
• In March 2025, VLP Therapeutics, Inc. (VLPT), a biotech company based in Maryland, USA, announced that it had received an investment of 885 million yen (roughly US$6 million) from the Global Health Innovative Technology (GHIT) Fund for a Phase I clinical trial of new dengue virus-like-particle (VLP) vaccines.

Segments Covered in the Report

By Type

• Live Attenuated Vaccine
• Chimeric Live Attenuated Vaccine
• Inactivated Vaccine
• Subunit Vaccine
• Nucleic Acid-Based Vaccine

By Route of Administration

• Oral
• Parenteral
• Others

By End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Region

• North America
  • U.S. 
  • Canada 
  • Mexico 
  • Rest of North America
• South America 
  • Brazil
  • Argentina
  • Rest of South America
• Europe
  • Western Europe 
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
• Eastern Europe
  • Austria
  • Russia & Belarus
  • Türkiye
  • Albania
  • Rest of Eastern Europe
• Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA 
  • GCC Countries
  • Saudi Arabia
  • United Arab Emirates (UAE)
  • Qatar
  • Kuwait
  • Oman
  • Bahrain
• South Africa
• Egypt
• Rest of MEA